-
1
-
-
72949132104
-
Factors of risk in the development of coronary heart disease - Six year follow-up experience. The Framingham Study
-
Kannel WB, Dawber TR, Kagan A, et al. Factors of risk in the development of coronary heart disease - six year follow-up experience. The Framingham Study. Ann Intern Med 1961;55:33-50
-
(1961)
Ann Intern Med
, vol.55
, pp. 33-50
-
-
Kannel, W.B.1
Dawber, T.R.2
Kagan, A.3
-
2
-
-
0025818120
-
Chronic renal failure: Pathophysiology
-
Jacobson HR. Chronic renal failure: pathophysiology. Lancet 1991;338:419-423
-
(1991)
Lancet
, vol.338
, pp. 419-423
-
-
Jacobson, H.R.1
-
3
-
-
0015333482
-
Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease
-
Laragh JH, Baer L, Brunner HR, et al. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972;52:633-652
-
(1972)
Am J Med
, vol.52
, pp. 633-652
-
-
Laragh, J.H.1
Baer, L.2
Brunner, H.R.3
-
4
-
-
0017045374
-
Role of hypertension in atherosclerosis and cardiovascular disease
-
Hollander W. Role of hypertension in atherosclerosis and cardiovascular disease. Am J Cardiol 1976;38:786-800
-
(1976)
Am J Cardiol
, vol.38
, pp. 786-800
-
-
Hollander, W.1
-
5
-
-
33845210475
-
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney
-
Crowley SD, Gurley SB, Herrera MJ, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006;103:17985-17990
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, pp. 17985-17990
-
-
Crowley, S.D.1
Gurley, S.B.2
Herrera, M.J.3
-
7
-
-
42049103473
-
Pleiotropic effects of telmisartan: Still more to come?
-
Benndorf RA, Boger RH. Pleiotropic effects of telmisartan: still more to come? J Hypertens 2008;26:854-856
-
(2008)
J Hypertens
, vol.26
, pp. 854-856
-
-
Benndorf, R.A.1
Boger, R.H.2
-
8
-
-
31444437343
-
Telmisartan: A review of its use in the management of hypertension
-
Battershill AJ, Scott LJ. Telmisartan: a review of its use in the management of hypertension. Drugs 2006;66(1):51-83
-
(2006)
Drugs
, vol.66
, Issue.1
, pp. 51-83
-
-
Battershill, A.J.1
Scott, L.J.2
-
9
-
-
19944372857
-
-
Telmisartan (Micardis) 60th edition. Montvale, NJ, Medical Economics
-
Telmisartan (Micardis-). Physicians' desk reference. 60th edition. Montvale, NJ, Medical Economics; 2005. p. 997-999
-
(2005)
Physicians' Desk Reference
, pp. 997-999
-
-
-
10
-
-
77953920477
-
-
(Dok.-Ref.: EMA/829297/2009; EMEA/H/C/210). Available from [Last accessed 31 March 2010]
-
EMEA document regarding the approval of telmisartan by the European commission. (Dok.-Ref.: EMA/829297/ 2009; EMEA/H/C/210). Available from: http://www.ema.europa.eu/humandocs/ PDFs/EPAR/Pritor/198798de1.pdf. [Last accessed 31 March 2010]
-
EMEA Document Regarding the Approval of Telmisartan by the European Commission
-
-
-
11
-
-
77953922394
-
-
from July 28, Available from [Last accessed 31 March 2010]
-
Micardis Briefing document for the Cardiovascular and Renal Drugs Advisory Committee (FDA) from July 28, 2009. Available from: http:// www.fda.gov/downloads/ AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisory Committee/UCM173529.pdf. [Last accessed 31 March 2010]
-
(2009)
Micardis Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (FDA)
-
-
-
12
-
-
0027218706
-
Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277
-
Wienen W, Hauel N, Van Meel JC, et al. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993;110:245-252
-
(1993)
Br J Pharmacol
, vol.110
, pp. 245-252
-
-
Wienen, W.1
Hauel, N.2
Van Meel, J.C.3
-
13
-
-
1542547460
-
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity
-
Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004;43:993-1002
-
(2004)
Hypertension
, vol.43
, pp. 993-1002
-
-
Benson, S.C.1
Pershadsingh, H.A.2
Ho, C.I.3
-
14
-
-
2442451618
-
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity
-
Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-2057
-
(2004)
Circulation
, vol.109
, pp. 2054-2057
-
-
Schupp, M.1
Janke, J.2
Clasen, R.3
-
15
-
-
33747131444
-
Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension
-
Benndorf RA, Rudolph T, Appel D, et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006;55:1159-1164
-
(2006)
Metabolism
, vol.55
, pp. 1159-1164
-
-
Benndorf, R.A.1
Rudolph, T.2
Appel, D.3
-
16
-
-
33847125757
-
Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension
-
Bajcetic M, Benndorf RA, Appel D, et al. Pharmacokinetics of oral doses of telmisartan and nisoldipine, given alone and in combination, in patients with essential hypertension. J Clin Pharmacol 2007;47:295-304
-
(2007)
J Clin Pharmacol
, vol.47
, pp. 295-304
-
-
Bajcetic, M.1
Benndorf, R.A.2
Appel, D.3
-
17
-
-
20344400660
-
Adipocyte signaling and lipid homeostasis: Sequelae of insulin-resistant adipose tissue
-
Yu YH, Ginsberg HN. Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res 2005;96:1042-1052
-
(2005)
Circ Res
, vol.96
, pp. 1042-1052
-
-
Yu, Y.H.1
Ginsberg, H.N.2
-
18
-
-
48449106424
-
Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan
-
Clemenz M, Frost N, Schupp M, et al. Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008;57:1405-1413
-
(2008)
Diabetes
, vol.57
, pp. 1405-1413
-
-
Clemenz, M.1
Frost, N.2
Schupp, M.3
-
19
-
-
67449108376
-
Peroxisome proliferator-activated receptor-alpha (PPARalpha): At the crossroads of obesity, diabetes and cardiovascular disease
-
Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009;205:1-8
-
(2009)
Atherosclerosis
, vol.205
, pp. 1-8
-
-
Fruchart, J.C.1
-
20
-
-
0035146287
-
Control of vascular cell proliferation and migration by PPAR-gamma: A new approach to the macrovascular complications of diabetes
-
Hsueh WA, Jackson S, Law RE. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 2001;24:392-397
-
(2001)
Diabetes Care
, vol.24
, pp. 392-397
-
-
Hsueh, W.A.1
Jackson, S.2
Law, R.E.3
-
21
-
-
40949119482
-
Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells
-
Cianchetti S, Del Fiorentino A, Colognato R, et al. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 2008;198:22-28
-
(2008)
Atherosclerosis
, vol.198
, pp. 22-28
-
-
Cianchetti, S.1
Del Fiorentino, A.2
Colognato, R.3
-
22
-
-
42049108222
-
Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: Are all molecules the same?
-
Benson SC, Iguchi R, Ho CI, et al. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same? J Hypertens 2008;26:973-980
-
(2008)
J Hypertens
, vol.26
, pp. 973-980
-
-
Benson, S.C.1
Iguchi, R.2
Ho, C.I.3
-
23
-
-
37449001505
-
Telmisartan improves endothelial function in patients with essential hypertension
-
Benndorf RA, Appel D, Maas R, et al. Telmisartan improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol 2007;50:367-371
-
(2007)
J Cardiovasc Pharmacol
, vol.50
, pp. 367-371
-
-
Benndorf, R.A.1
Appel, D.2
Maas, R.3
-
24
-
-
0033740069
-
Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers
-
Stangier J, Schmid J, Turck D, et al. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1312-1322
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 1312-1322
-
-
Stangier, J.1
Schmid, J.2
Turck, D.3
-
25
-
-
0033840660
-
Pharmacokinetics of orally and intravenous administered telmisartan in healthy young and elderly volunteers and in hypertensive patients
-
Stangier J, Su CA, Roth W, et al. Pharmacokinetics of orally and intravenous administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000;28:149-172
-
(2000)
J Int Med Res
, vol.28
, pp. 149-172
-
-
Stangier, J.1
Su, C.A.2
Roth, W.3
-
26
-
-
33745253947
-
Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans
-
Ishiguro N, Maeda K, Kishimoto W, et al. Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 2006;34:1109-1115
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 1109-1115
-
-
Ishiguro, N.1
Maeda, K.2
Kishimoto, W.3
-
27
-
-
41549098278
-
Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide
-
Ishiguro N, Maeda K, Saito A, et al. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 2008;36:796-805
-
(2008)
Drug Metab Dispos
, vol.36
, pp. 796-805
-
-
Ishiguro, N.1
Maeda, K.2
Saito, A.3
-
28
-
-
77953933130
-
-
Micardis full prescribing information of the EMEA. Available from [Last accessed 5 May 2010]
-
Micardis full prescribing information of the EMEA. Available from: http:// www.ema.europa.eu/humandocs/PDFs/ EPAR/Micardis/emea-combined-h209en. pdf. [Last accessed 5 May 2010]
-
-
-
-
29
-
-
77953946421
-
-
Available from[Last accessed 5 May 2010]
-
Micardis full prescribing information of the FDA. Available from: http:// www.accessdata.fda.gov/drugsatfda-docs/ label/2009/020850s025lbl.pdf. [Last accessed 5 May 2010]
-
Micardis Full Prescribing Information of the FDA
-
-
-
30
-
-
0029128720
-
Gender effects in pharmacokinetics and pharmacodynamics
-
Harris RZ, Benet LZ, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50:222-239
-
(1995)
Drugs
, vol.50
, pp. 222-239
-
-
Harris, R.Z.1
Benet, L.Z.2
Schwartz, J.B.3
-
31
-
-
0033749163
-
Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: Comparison with healthy volunteers
-
Stangier J, Su Chung-An PF, Brickl R, et al. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 2000;40:1365-1372
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 1365-1372
-
-
Stangier, J.1
Su Chung-An, P.F.2
Brickl, R.3
-
32
-
-
70349603042
-
Pharmacokinetics and dosage adjustment in patients with renal dysfunction
-
Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 2009;65:757-773
-
(2009)
Eur J Clin Pharmacol
, vol.65
, pp. 757-773
-
-
Verbeeck, R.K.1
Musuamba, F.T.2
-
33
-
-
0033748477
-
Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers
-
Stangier J, Su Chung-An PF, Schondorfer G, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharamcol 2000;40:1355-1364
-
(2000)
J Clin Pharamcol
, vol.40
, pp. 1355-1364
-
-
Stangier, J.1
Su Chung-An, P.F.2
Schondorfer, G.3
-
34
-
-
0043124614
-
Drug interactions with angiotensin receptor blockers: A comparison with other antihypertensives
-
Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Saf 2003;26:707-720
-
(2003)
Drug Saf
, vol.26
, pp. 707-720
-
-
Unger, T.1
Kaschina, E.2
-
35
-
-
77951031222
-
Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters
-
Weiss J, Sauer A, Divac N, et al. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos 2010;31:150-161
-
(2010)
Biopharm Drug Dispos
, vol.31
, pp. 150-161
-
-
Weiss, J.1
Sauer, A.2
Divac, N.3
-
36
-
-
0033731288
-
Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers
-
Stangier J, Su C-APF. Pharmacokinetics of repeated oral doses of amlodipine and amlodipine plus telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1347-1354
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 1347-1354
-
-
Stangier, J.1
C-Apf, S.2
-
38
-
-
42049107348
-
The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events
-
Yusuf S, Teo KK, Pogue J, et al. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
-
(2008)
N Engl J Med
, vol.358
, pp. 1547-1559
-
-
Yusuf, S.1
Teo, K.K.2
Pogue, J.3
-
39
-
-
0033732238
-
Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers
-
Stangier J, Su C-APF, Hendriks MGC, et al. Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. J Clin Pharmacol 2000;40:1331-1337
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 1331-1337
-
-
Stangier, J.1
C-Apf, S.2
Mgc, H.3
-
40
-
-
0033749283
-
Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers
-
Stangier J, Su C-APF, Fraunhofer A, et al. Pharmacokinetics of acetaminophen and ibuprofen when coadministered with telmisartan in healthy volunteers. J Clin Pharmacol 2000;40:1338-1346
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 1338-1346
-
-
Stangier, J.1
C-Apf, S.2
Fraunhofer, A.3
-
41
-
-
0033747596
-
Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects
-
Yong C-L, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000;40:1323-1330
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 1323-1330
-
-
Yong, C.-L.1
Dias, V.C.2
Stangier, J.3
-
42
-
-
0033815393
-
Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisartan
-
Nishino A, Kato Y, Igarashi T, et al. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisartan. Drug Metab Dispos 2000;28:1146-1148
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 1146-1148
-
-
Nishino, A.1
Kato, Y.2
Igarashi, T.3
-
43
-
-
57049170781
-
Telmisartan pharmacokinetics in Japanese renal transplant recipients
-
Miura M, Satoh S, Inoue K, et al. Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin Chim Acta 2009;399:83-87
-
(2009)
Clin Chim Acta
, vol.399
, pp. 83-87
-
-
Miura, M.1
Satoh, S.2
Inoue, K.3
-
44
-
-
58149263115
-
No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects
-
Guo X, Chen XP, Cheng ZN, et al. No effect of MDR1 C3435T polymorphism on oral pharmacokinetics of telmisartan in 19 healthy Chinese male subjects. Clin Chem Lab Med 2009;47:38-43
-
(2009)
Clin Chem Lab Med
, vol.47
, pp. 38-43
-
-
Guo, X.1
Chen, X.P.2
Cheng, Z.N.3
-
45
-
-
33751525373
-
Rapid identification of P-glycoprotein substrates and inhibitors
-
Chang C, Bahadduri PM, Polli JE, et al. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 2006;34:1976-1984
-
(2006)
Drug Metab Dispos
, vol.34
, pp. 1976-1984
-
-
Chang, C.1
Bahadduri, P.M.2
Polli, J.E.3
-
46
-
-
58549088199
-
Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug
-
Fenner KS, Troutman MD, Kempshall S, et al. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 2009;85:173-181
-
(2009)
Clin Pharmacol Ther
, vol.85
, pp. 173-181
-
-
Fenner, K.S.1
Troutman, M.D.2
Kempshall, S.3
-
47
-
-
77449143886
-
Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes
-
Kamiyama E, Nakai D, Mikkaichi T, et al. Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci 2010;86:52-58
-
(2010)
Life Sci
, vol.86
, pp. 52-58
-
-
Kamiyama, E.1
Nakai, D.2
Mikkaichi, T.3
-
48
-
-
0033748479
-
The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers
-
Stangier J, Su C-APF, Hendriks MGC, et al. The effect of telmisartan on the steady-state pharmacokinetics of digoxin in healthy male volunteers. J Clin Pharmacol 2000;40:1373-1379
-
(2000)
J Clin Pharmacol
, vol.40
, pp. 1373-1379
-
-
Stangier, J.1
C-Apf, S.2
Mgc, H.3
-
49
-
-
12344282783
-
Global burden of hypertension: Analysis of worldwide data
-
Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-223
-
(2005)
Lancet
, vol.365
, pp. 217-223
-
-
Kearney, P.M.1
Whelton, M.2
Reynolds, K.3
-
50
-
-
0347423198
-
Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure. National Heart Lung and Blood Institute; National High Blood Pressure Education Program Coordinating CommitteeSeventh report of the Joint National Committee on Prevention Detection Evaluation and Treatment of High Blood Pressure
-
Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating CommitteeSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252
-
(2003)
Hypertension
, vol.42
, pp. 1206-1252
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
51
-
-
0041589771
-
Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension - A randomised ABPM study
-
Neutel JM, Kolloch RE, Plouin PF, et al. Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension - a randomised ABPM study. J Hum Hypertens 2003;17:569-575
-
(2003)
J Hum Hypertens
, vol.17
, pp. 569-575
-
-
Neutel, J.M.1
Kolloch, R.E.2
Plouin, P.F.3
-
52
-
-
10344250394
-
Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: A multicentre, randomised, double-blind study
-
Zhu JR, Bai J, Cai NS, et al. Efficacy and safety of telmisartan vs. losartan in control of mild-to-moderate hypertension: a multicentre, randomised, double-blind study. Int J Clin Pract Suppl 2004;145:46-49
-
(2004)
Int J Clin Pract Suppl
, vol.145
, pp. 46-49
-
-
Zhu, J.R.1
Bai, J.2
Cai, N.S.3
-
53
-
-
0033784560
-
A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring
-
Littlejohn T, Mroczek W, Marbury T, et al. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000;16:1123-1132
-
(2000)
Can J Cardiol
, vol.16
, pp. 1123-1132
-
-
Littlejohn, T.1
Mroczek, W.2
Marbury, T.3
-
54
-
-
1842562367
-
Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: Impact on the early morning period
-
White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004;17:347-353
-
(2004)
Am J Hypertens
, vol.17
, pp. 347-353
-
-
White, W.B.1
Lacourciere, Y.2
Davidai, G.3
-
55
-
-
44949104716
-
Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension
-
Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008;68:1207-1225
-
(2008)
Drugs
, vol.68
, pp. 1207-1225
-
-
Smith, D.H.1
-
56
-
-
0141753977
-
Blood pressure- and pulse pressure-lowering effects, trough: Peak ratio and smoothness index of telmisartan compared with lisinopril
-
Stergiou GS, Efstathiou SP, Roussias LG, Mountokalakis TD. Blood pressure- and pulse pressure-lowering effects, trough: peak ratio and smoothness index of telmisartan compared with lisinopril. J Cardiovasc Pharmacol 2003;42:491-496
-
(2003)
J Cardiovasc Pharmacol
, vol.42
, pp. 491-496
-
-
Stergiou, G.S.1
Efstathiou, S.P.2
Roussias, L.G.3
Mountokalakis, T.D.4
-
57
-
-
0036810631
-
Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: A review of clinical studies of telmisartan and enalapril
-
Smith DH. Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor: a review of clinical studies of telmisartan and enalapril. Clin Ther 2002;24:1484-1501
-
(2002)
Clin Ther
, vol.24
, pp. 1484-1501
-
-
Smith, D.H.1
-
58
-
-
10344251467
-
Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension
-
Alcocer L, Fernandez-Bonetti P, Campos E, et al. Clinical efficacy and safety of telmisartan 80 mg once daily vs. atenolol 50 mg once daily in patients with mild-to-moderate hypertension. Int J Clin Pract Suppl 2004;145:35-39
-
(2004)
Int J Clin Pract Suppl
, vol.145
, pp. 35-39
-
-
Alcocer, L.1
Fernandez-Bonetti, P.2
Campos, E.3
-
59
-
-
0032423365
-
A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine
-
Lacourciere Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998;3:295-302
-
(1998)
Blood Press Monit
, vol.3
, pp. 295-302
-
-
Lacourciere, Y.1
Lenis, J.2
Orchard, R.3
-
60
-
-
0035153980
-
Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: A randomized, multicenter study
-
Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group
-
Freytag F, Schelling A, Meinicke T, et al. Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001;23:108-123
-
(2001)
Clin Ther
, vol.23
, pp. 108-123
-
-
Freytag, F.1
Schelling, A.2
Meinicke, T.3
-
61
-
-
0347765700
-
The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy
-
Gil-Extremera B, Ma PT, Yulde J, et al. The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy. Int J Clin Pract 2003;57:861-866
-
(2003)
Int J Clin Pract
, vol.57
, pp. 861-866
-
-
Gil-Extremera, B.1
Ma, P.T.2
Yulde, J.3
-
62
-
-
0034688194
-
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
-
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153
-
(2000)
N Engl J Med
, vol.342
, pp. 145-153
-
-
Yusuf, S.1
Sleight, P.2
Pogue, J.3
-
63
-
-
0042330455
-
EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)
-
Fox KM. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788
-
(2003)
Lancet
, vol.362
, pp. 782-788
-
-
Fox, K.M.1
-
64
-
-
19644400972
-
PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease
-
Braunwald E, Domanski MJ, Fowler SE, et al. PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068
-
(2004)
N Engl J Med
, vol.351
, pp. 2058-2068
-
-
Braunwald, E.1
Domanski, M.J.2
Fowler, S.E.3
-
65
-
-
0030902115
-
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
-
Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752
-
(1997)
Lancet
, vol.349
, pp. 747-752
-
-
Pitt, B.1
Segal, R.2
Martinez, F.A.3
-
66
-
-
0041408235
-
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-added trial
-
DOI 10.1016/S0140-6736(03)14283-3
-
McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-771 (Pubitemid 37093916)
-
(2003)
Lancet
, vol.362
, Issue.9386
, pp. 767-771
-
-
McMurray, J.J.V.1
Ostergren, J.2
Swedberg, K.3
Granger, C.B.4
Held, P.5
Michelson, E.L.6
Olofsson, B.7
Yusuf, S.8
Pfeffer, M.A.9
-
67
-
-
3142740224
-
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials
-
ONTARGET/TRANSCEND Investigators
-
Teo K, Yusuf S, Sleight P, et al. ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/ Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/ TRANSCEND) trials. Am Heart J 2004;148:52-61
-
(2004)
Am Heart J
, vol.148
, pp. 52-61
-
-
Teo, K.1
Yusuf, S.2
Sleight, P.3
-
68
-
-
53049109468
-
Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial
-
Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-1183
-
(2008)
Lancet
, vol.372
, pp. 1174-1183
-
-
Yusuf, S.1
Teo, K.2
Anderson, C.3
-
69
-
-
51449085994
-
Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: A double-blind, active and placebo-controlled study
-
Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group
-
Diener HC, Sacco RL, Yusuf S, et al. Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol 2008;7:875-884
-
(2008)
Lancet Neurol
, vol.7
, pp. 875-884
-
-
Diener, H.C.1
Sacco, R.L.2
Yusuf, S.3
-
70
-
-
0034888870
-
Discontinuation of antihypertensive drugs due to adverse events: A systematic review and meta-analysis
-
Ross SD, Akhras KS, Zhang S, et al. Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis. Pharmacotherapy 2001;21:940-953
-
(2001)
Pharmacotherapy
, vol.21
, pp. 940-953
-
-
Ross, S.D.1
Akhras, K.S.2
Zhang, S.3
-
71
-
-
1942467808
-
Safety of telmisartan in patients with arterial hypertension: An open-label observational study
-
Michel MC, Bohner H, Koster J, et al. Safety of telmisartan in patients with arterial hypertension: an open-label observational study. Drug Saf 2004;27:335-344
-
(2004)
Drug Saf
, vol.27
, pp. 335-344
-
-
Michel, M.C.1
Bohner, H.2
Koster, J.3
-
72
-
-
0032896412
-
Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension
-
Neutel JM, Frishman WH, Oparil S, et al. Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999;6:161-166
-
(1999)
Am J Ther
, vol.6
, pp. 161-166
-
-
Neutel, J.M.1
Frishman, W.H.2
Oparil, S.3
-
73
-
-
29244484441
-
The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I)
-
PRISMA I Study Group
-
Williams B, Gosse P, Lowe L, et al. PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens 2006;24:193-200
-
(2006)
J Hypertens
, vol.24
, pp. 193-200
-
-
Williams, B.1
Gosse, P.2
Lowe, L.3
-
74
-
-
0035528585
-
Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension
-
French Collaborative Telmisartan Study Group
-
Hannedouche T, Chanard J, Baumelou B. French Collaborative Telmisartan Study Group. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2001;2:246-254
-
(2001)
J Renin Angiotensin Aldosterone Syst
, vol.2
, pp. 246-254
-
-
Hannedouche, T.1
Chanard, J.2
Baumelou, B.3
-
75
-
-
25844453959
-
Ventricular and vascular remodelling: Effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients
-
Petrovic J, Petrovic D, Vukovic N, et al. Ventricular and vascular remodelling: effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005;33:39-49A
-
(2005)
J Int Med Res
, vol.33
-
-
Petrovic, J.1
Petrovic, D.2
Vukovic, N.3
|